Clinical trials / NCT-BPC203-101

phase 1 · Recruiting

Phase 1 first-in-human study of BPC-203 in B-cell lymphoma

First-in-human dose escalation study of BPC-203, a humanized anti-CD19 monoclonal antibody with engineered Fc, in relapsed or refractory B-cell lymphoma.

BPC-203 Sample data

Investigational candidate. BPC-203 has not been approved by any regulatory authority.

Enrollment

Patient participation.

Enrolled 32
Target 60
Sites 4

53% of target enrollment reached.

Design

Trial endpoints.

Primary endpoint

Safety and dose-limiting toxicities.

Secondary endpoints

  • Pharmacokinetics
  • Antitumor activity by Lugano 2014 criteria

Eligibility

Adults with relapsed or refractory CD19+ B-cell lymphoma after at least two prior lines of therapy.

Timeline

Started
August 1, 2024

Sites

4 sites for NCT-BPC203-101.

  • Basel Research Laboratory

    Grenzacherstrasse 250, 4058 Basel

    Basel, Switzerland

  • University Hospital Zurich

    Rämistrasse 100, 8091 Zürich

    Zurich, Switzerland

  • London Cancer Institute

    250 Euston Road, London NW1 2PG

    London, United Kingdom

  • Toronto Health Network

    200 Elizabeth Street, Toronto, ON M5G 2C4

    Toronto, Canada
Back to trials View BPC-203